<DOC>
	<DOCNO>NCT01766336</DOCNO>
	<brief_summary>To evaluate safety tolerability ELND005 treatment 36 week exposure , Moderate Severe AD patient agitation aggression .</brief_summary>
	<brief_title>A 36-Week Safety Extension Study ELND005 Treatment Agitation Aggression Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<criteria>Complete Week 12 visit AG201 Both patient study partner/caregiver willing able participate schedule evaluation complete required test Is currently use investigational experimental drug device Has significant worsen medical condition dementia may preclude completion safety extension study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Agitation</keyword>
	<keyword>Aggression</keyword>
	<keyword>AD patient</keyword>
</DOC>